$MYO
MYOMO, INC.

2018 Q1 Form 10-K Financial Statement

#000119312518079222 Filed on March 12, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $313.2K $1.559M $450.0K
YoY Change 44.84% 41.29%
Cost Of Revenue $108.1K $505.3K $100.0K
YoY Change 37.56% 79.07%
Gross Profit $205.1K $1.054M $350.0K
YoY Change 48.99% 28.31%
Gross Profit Margin 65.49% 67.59% 77.78%
Selling, General & Admin $2.236M $5.850M $1.040M
YoY Change 95.34% 96.63%
% of Gross Profit 1090.03% 555.24% 297.14%
Research & Development $372.4K $1.752M $410.0K
YoY Change 4.34% 56.27%
% of Gross Profit 181.55% 166.26% 117.14%
Depreciation & Amortization $14.60K $11.42K $0.00
YoY Change 573.08% 47.65%
% of Gross Profit 7.12% 1.08% 0.0%
Operating Expenses $2.608M $7.602M $1.450M
YoY Change 73.71% 85.58%
Operating Profit -$2.403M -$6.548M -$1.100M
YoY Change 76.21% 99.94%
Interest Expense $42.19K -$358.9K -$110.0K
YoY Change -125.13% 4.94%
% of Operating Profit
Other Income/Expense, Net $57.50K -$5.549M
YoY Change -129.83% 1522.53%
Pretax Income -$2.350M -$12.10M -$1.210M
YoY Change 50.64% 234.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.345M -$12.10M -$1.210M
YoY Change 50.69% 234.46%
Net Earnings / Revenue -748.9% -776.04% -268.89%
Basic Earnings Per Share
Diluted Earnings Per Share -$197.5K -$84.06M -$1.080M
COMMON SHARES
Basic Shares Outstanding 12.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.12M $12.96M
YoY Change 1525.67%
Cash & Equivalents $14.12M $12.96M $797.2K
Short-Term Investments
Other Short-Term Assets $370.0K $388.3K
YoY Change 154.88%
Inventory $237.9K $201.2K $82.44K
Prepaid Expenses
Receivables $151.4K $297.0K $114.5K
Other Receivables $0.00 $0.00
Total Short-Term Assets $14.88M $13.85M $1.146M
YoY Change 1107.71%
LONG-TERM ASSETS
Property, Plant & Equipment $155.3K $77.15K $21.56K
YoY Change 257.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.00K $52.00K
YoY Change -89.39%
Total Long-Term Assets $207.3K $129.2K $511.8K
YoY Change -74.77%
TOTAL ASSETS
Total Short-Term Assets $14.88M $13.85M $1.146M
Total Long-Term Assets $207.3K $129.2K $511.8K
Total Assets $15.09M $13.97M $1.658M
YoY Change 742.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $240.0K $1.277M
YoY Change 78.88%
Accrued Expenses $710.0K $0.00 $149.6K
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.117M $1.485M $3.001M
YoY Change -50.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $50.00K $44.04K
YoY Change -66.37%
Total Long-Term Liabilities $50.00K $44.04K $3.515M
YoY Change -98.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.117M $1.485M $3.001M
Total Long-Term Liabilities $50.00K $44.04K $3.515M
Total Liabilities $1.162M $1.529M $6.516M
YoY Change -76.53%
SHAREHOLDERS EQUITY
Retained Earnings -$37.32M -$22.88M
YoY Change
Common Stock $1.240K $112.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K $6.464K
YoY Change
Treasury Stock Shares 808.0 shares 808.0 shares
Shareholders Equity $13.92M $12.45M -$17.53M
YoY Change
Total Liabilities & Shareholders Equity $15.09M $13.97M $1.658M
YoY Change 742.76%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$2.345M -$12.10M -$1.210M
YoY Change 50.69% 234.46%
Depreciation, Depletion And Amortization $14.60K $11.42K $0.00
YoY Change 573.08% 47.65%
Cash From Operating Activities -$2.265M -$6.153M -$900.0K
YoY Change 94.99% 92.13%
INVESTING ACTIVITIES
Capital Expenditures $64.92K $67.00K $0.00
YoY Change 1426.9% 3492.6%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$64.92K -$67.00K $0.00
YoY Change 1426.9% 3492.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.41M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.487M 18.38M 1.210M
YoY Change 96.72% 521.23%
NET CHANGE
Cash From Operating Activities -2.265M -6.153M -900.0K
Cash From Investing Activities -64.92K -67.00K 0.000
Cash From Financing Activities 3.487M 18.38M 1.210M
Net Change In Cash 1.157M 12.16M 310.0K
YoY Change 90.71% -5055.18%
FREE CASH FLOW
Cash From Operating Activities -$2.265M -$6.153M -$900.0K
Capital Expenditures $64.92K $67.00K $0.00
Free Cash Flow -$2.330M -$6.220M -$900.0K
YoY Change 99.85% 94.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 myo Fair Value Measurements Warrants Outstanding
FairValueMeasurementsWarrantsOutstanding
156725
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5600000 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4100000 shares
CY2017Q4 us-gaap Share Price
SharePrice
6.29
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12392536 shares
CY2017Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
125000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.47
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3591 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.25
CY2017Q2 dei Entity Public Float
EntityPublicFloat
35443695
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1042618
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8228 shares
CY2015Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2239
CY2015Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2994
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
207146
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
272494 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.1088
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-13901662
CY2015Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
8228 shares
CY2015Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
6.47
CY2015Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
6.47
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
221630
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
714010
CY2016Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
6600
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
149580
CY2016Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
130937
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2016Q4 us-gaap Assets Current
AssetsCurrent
1146452
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
114506
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3001295
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20345
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5351204
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
311085
CY2016Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
24500
CY2016Q4 us-gaap Assets
Assets
1658252
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
797174
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1124080 shares
CY2016Q4 us-gaap Cash
Cash
0
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8228 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1124888 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
112
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
67263
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8224000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2204235
CY2016Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
438237
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7876000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
189000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
140000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8224000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
19000
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
81223
CY2016Q4 us-gaap Inventory Net
InventoryNet
82435
CY2016Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
9000000
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
82435
CY2016Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1213
CY2016Q4 us-gaap Liabilities
Liabilities
6516467
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1658252
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3515172
CY2016Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
876458
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
103969
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
152337
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21563
CY2016Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
63147
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
41908
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
52000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22875308
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
99879
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
132121
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
140724 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.3464
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
246344 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.5133
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-17530456
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12672241
CY2016Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
808 shares
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
808 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2016Q4 myo Convertible Debt Related Party Noncurrent
ConvertibleDebtRelatedPartyNoncurrent
1180000
CY2016Q4 myo Federal State And Local Income Tax Expense Benefit
FederalStateAndLocalIncomeTaxExpenseBenefit
-1361000
CY2016Q4 myo Accrued Offering Costs Current
AccruedOfferingCostsCurrent
77326
CY2016Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
8228 shares
CY2016Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
6.47
CY2016Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
6.47
CY2016Q4 myo Notes Payable Current Mlsc
NotesPayableCurrentMlsc
1193984
CY2016Q4 myo Redeemable And Convertible Preferred Stock And Stockholders Equity Deficiency
RedeemableAndConvertiblePreferredStockAndStockholdersEquityDeficiency
-4858215
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
642425
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1277236
CY2017Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
65800
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2017Q4 us-gaap Assets Current
AssetsCurrent
13845842
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
297039
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
100000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31760
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47423915
CY2017Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
264890
CY2017Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
77600
CY2017Q4 us-gaap Assets
Assets
13974992
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12959373
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11138859 shares
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10459435
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6277443 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11139667 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1114
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
168006
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6387000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5925000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
190000
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
39930
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
219000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6387000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
44042
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
53000
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
39930
CY2017Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
122000
CY2017Q4 us-gaap Inventory Net
InventoryNet
201155
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
23739
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
243510
CY2017Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
23530
CY2017Q4 us-gaap Liabilities
Liabilities
1529214
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13974992
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1485172
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
269921
CY2017Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
97980
CY2017Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
1700000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
388275
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77150
CY2017Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
50725
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
108910
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
52000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34972787
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
433960
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
732399
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
141847 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.6906
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
369004 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.7652
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
808 shares
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2017Q4 myo Offering Costs
OfferingCosts
622921
CY2017Q4 myo Federal State And Local Income Tax Expense Benefit
FederalStateAndLocalIncomeTaxExpenseBenefit
-1072000
CY2017Q4 myo Operating Loss Carryforwards Limitations
OperatingLossCarryforwardsLimitations
1559000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
12445778
CY2017Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
808 shares
CY2017Q4 myo Operating Loss Carryforwards Unutilized
OperatingLossCarryforwardsUnutilized
5000000
CY2017Q4 myo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
6193943 shares
CY2016Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625 pure
CY2017Q2 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2017-06-08
CY2017Q2 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2019-06-08
CY2017Q4 myo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
3.86
CY2017Q4 myo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
3.85
CY2017Q4 myo Fair Value Measurements Warrants Outstanding
FairValueMeasurementsWarrantsOutstanding
39930
CY2017Q4 myo Redeemable And Convertible Preferred Stock And Stockholders Equity Deficiency
RedeemableAndConvertiblePreferredStockAndStockholdersEquityDeficiency
12445778
CY2017Q4 myo Inventory Reserves Under Consignment
InventoryReservesUnderConsignment
18616
CY2017Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P30D
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10000000
CY2017Q2 myo Percentage Of Common Stock Price Per Share
PercentageOfCommonStockPricePerShare
0.80 pure
CY2017Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2000000
CY2017Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1081135
CY2017Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
1081135
CY2017Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86004
CY2017Q4 myo Percentage Of Common Stock Price Per Share
PercentageOfCommonStockPricePerShare
0.80 pure
CY2017Q4 myo Period Before Which Company Elects To Repay Notes In Shares Of Equity Following Financing By Company Of Equity Or Equity Linked Securities
PeriodBeforeWhichCompanyElectsToRepayNotesInSharesOfEquityFollowingFinancingByCompanyOfEquityOrEquityLinkedSecurities
P90D
CY2017Q4 myo Percentage Of Price Per Share
PercentageOfPricePerShare
0.80 pure
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7916620
CY2017Q2 myo Warrants Outstanding Common Stock Exercise Price Per Share
WarrantsOutstandingCommonStockExercisePricePerShare
7.50
CY2017Q2 myo Warrant Outstanding To Purchase Common Stock
WarrantOutstandingToPurchaseCommonStock
557216 shares
CY2015 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M12D
CY2017 us-gaap Advertising Expense
AdvertisingExpense
31000
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
17765
CY2017 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
5172000
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
156725
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
279508
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6646447 shares
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5172000
CY2017 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-116795
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12162199
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
11600
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
505280
CY2017 us-gaap Cost Of Services
CostOfServices
356400
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-534000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2909000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-538000
CY2017 us-gaap Depreciation
Depreciation
11415
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.93
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1519 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0467 pure
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y5M9D
CY2017 dei Entity Registrant Name
EntityRegistrantName
MYOMO INC
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001369290
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.2303 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0003 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Domestic
EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic
-0.1402 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
0.0089 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.63 pure
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0220 pure
CY2017 us-gaap Gross Profit
GrossProfit
1053586
CY2017 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
116795
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-135244
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
144785
CY2017 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-377503
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
182533
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
161075
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
563225
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
235938
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
42355
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-358916
CY2017 us-gaap Interest Paid
InterestPaid
97099
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
31845
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Note 1 &#x2014; Description of Business</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Myomo Inc. (&#x201C;Myomo&#x201D; or the Company&#x201D;) is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class&#xA0;II medical device. The Company sells the product to orthotics and prosthetics practices or clinics, as well as the Veteran Administration and other hospitals in the United States of America, and, beginning in 2017, through a distribution agreement with Otto Bock Healthcare L.P. (&#x201C;Ottobock&#x201D;). The Company was incorporated in the State of Delaware on September&#xA0;1, 2004 and is headquartered in Cambridge, Massachusetts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Initial Public Offering under Regulation A and Private Placement under Regulation D</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On June&#xA0;9, 2017, the Company completed its initial public offering (&#x201C;IPO&#x201D;) under Regulation A of the Securities Act of 1933, as amended, raising $4,991,235, before selling agent and other offering expenses of $1,061,157, through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. On June&#xA0;9, 2017, the Company also closed on a private placement under Regulation D Rule 506(b) pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consisted of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share. The combined aggregate gross proceeds raised were $7,916,620.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In connection with the closing of the Company&#x2019;s IPO on June&#xA0;9, 2017, the Company filed an amended and restated certificate of incorporation and restated bylaws, both of which were approved by the Company&#x2019;s board of directors and stockholders on October&#xA0;23, 2016. Pursuant to the amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i><font style="WHITE-SPACE: nowrap">Follow-on</font>&#xA0;Public Offering</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On December&#xA0;4, 2017, the Company completed a&#xA0;<font style="WHITE-SPACE: nowrap">follow-on</font>&#xA0;public offering (&#x201C;FPO&#x201D;) in which the Company sold 4,175,000 shares of its common stock and 4,175,000 warrants to purchase shares of its common stock, at a price to the public of $2.40. The warrants are exercisable at an exercise price of $2.95 per share of common stock, and they expire on December&#xA0;4, 2022. On December&#xA0;6, 2017, the Company&#x2019;s underwriters on the FPO exercised in full its option to purchase 626,250 shares of common stock and accompanying warrant at a combined price to the public of $2.40 per combination. After giving effect to the full exercise of the over-allotment, the Company sold an aggregate of 4,801,250 shares of common stock and accompanying warrants to purchase an aggregate of 4,801,250 shares of common stock, raising $11,523,000 before underwriting discounts and other offering expenses of $1,115,000.</p> </div>
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12659269
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67002
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18382620
CY2017 us-gaap Operating Expenses
OperatingExpenses
7601700
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6153419
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12097479
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-6548114
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
221200
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5549365
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67002
CY2017 us-gaap Preferred Stock Redemption Premium
PreferredStockRedemptionPremium
274011
CY2017 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Reclassification</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Certain amounts in the 2016 financial statements of operations have been reclassified to conform to the 2017 presentation. These reclassifications had no impact on previously reported net loss.</p> </div>
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10407706
CY2017 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
14867
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1770000
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2922885
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
4368315
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26954
CY2017 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
27859
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
102660
CY2017 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
570
CY2017 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1215900
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1751731
CY2017 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
0
CY2017 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
53500
CY2017 us-gaap Revenues
Revenues
1558866
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
279508
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7855 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M24D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.3366
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5849969
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M20D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.62
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.6568
CY2017 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
156725
CY2017 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2922885
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
6304015 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.9717
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
210600 shares
CY2017 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
Three-year
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80085 shares
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12946252
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
279508
CY2017 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
One-for sixteen
CY2017 us-gaap Stock Issued1
StockIssued1
1217172
CY2017 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
5467389
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26954
CY2017 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
287779
CY2017 dei Trading Symbol
TradingSymbol
MYO
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4317864 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1837000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an <font style="WHITE-SPACE: nowrap">on-going</font> basis and updated as appropriate. Actual results could differ from those estimates. The Company&#x2019;s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving inventory.</p> </div>
CY2017 myo Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
274011
CY2017 myo Gross Proceeds From Initial Public Offering
GrossProceedsFromInitialPublicOffering
4991236
CY2017 myo Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
12946252
CY2017 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
102660
CY2017 myo Common Stock Issued For Warrants Exercised Shares
CommonStockIssuedForWarrantsExercisedShares
34800 shares
CY2017 myo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
6220515 shares
CY2017 myo Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
34800 shares
CY2017 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
-34800 shares
CY2017 myo Product Warranty Period
ProductWarrantyPeriod
P3Y
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Domestic
EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic
0.0000 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements State And Local
EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
-0.0054 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.81 pure
CY2017 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
3.84
CY2017 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
2.95
CY2017 myo Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Ultimate Settlement
IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponUltimateSettlement
0.50 pure
CY2017 myo Effective Income Tax Rate Reconciliation Nondeductible Interest
EffectiveIncomeTaxRateReconciliationNondeductibleInterest
-0.1767 pure
CY2017 myo Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
5172000
CY2017 myo Stock Issued During Period Value Repayment Of Notes
StockIssuedDuringPeriodValueRepaymentOfNotes
1217172
CY2017 myo Stock Issued During Period Value Issued For License Agreement
StockIssuedDuringPeriodValueIssuedForLicenseAgreement
1845
CY2017 myo Conversion Of Accrued Interest To Principal
ConversionOfAccruedInterestToPrincipal
21916
CY2017 myo Conversion Of Accrued Interest On Convertible Notes In To Common Stock
ConversionOfAccruedInterestOnConvertibleNotesInToCommonStock
5467389
CY2017 myo Exchange Of Convertible Promissory Notes
ExchangeOfConvertiblePromissoryNotes
430000
CY2017 myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
116795
CY2017 myo Issuance Of Selling Agent Warrants In Connection With Ipo
IssuanceOfSellingAgentWarrantsInConnectionWithIpo
156725
CY2017 myo Offering Cost From Sale Of Private Placement
OfferingCostFromSaleOfPrivatePlacement
2500
CY2017 myo Deferred Offering Costs To Additional Paid In Capital Upon Ipo Closing
DeferredOfferingCostsToAdditionalPaidInCapitalUponIpoClosing
438237
CY2017 myo Warrants Issued Description
WarrantsIssuedDescription
The Company issued warrants that expire in 2021 for the purchase of an aggregate of 8,228 shares of stock at an exercise price of $6.47 per share.
CY2017 myo Tax Cuts And Jobs Act Of2017 Change In Tax Rate Revaluation Of Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateRevaluationOfDeferredTaxAssets
3383000
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0058 pure
CY2016 myo Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
108739
CY2016 myo Product Warranty Period
ProductWarrantyPeriod
P1Y
CY2016 myo Conversion Of Accrued Interest To Principal
ConversionOfAccruedInterestToPrincipal
443984
CY2016 myo Increase Decrease In Restricted Cash Noncurrent
IncreaseDecreaseInRestrictedCashNoncurrent
52000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
44538
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
38461
CY2016 us-gaap Gross Profit
GrossProfit
821113
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePriceExercisable
3.85
CY2017 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable
2.95
CY2017 myo Preferred Stock Accretion Of Redemption Discount Premium
PreferredStockAccretionOfRedemptionDiscountPremium
274011
CY2016 us-gaap Advertising Expense
AdvertisingExpense
41600
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5347
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
94094
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2879312 shares
CY2016 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-2329
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-245444
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
10100
CY2016 us-gaap Cost Of Revenue
CostOfRevenue
282164
CY2016 us-gaap Cost Of Services
CostOfServices
156900
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1184000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-177000
CY2016 us-gaap Depreciation
Depreciation
7731
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.13
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3862 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0545 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y
CY2016 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.25 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0029 pure
CY2016 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-299175
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1136
CY2016 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
431961
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-120588
CY2016 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
364165
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-342020
CY2016 us-gaap Interest Paid
InterestPaid
37619
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4384054
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1865
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2959091
CY2016 us-gaap Operating Expenses
OperatingExpenses
4096115
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3202670
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-3617022
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-3275002
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
108400
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-342020
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1865
CY2016 us-gaap Preferred Stock Redemption Premium
PreferredStockRedemptionPremium
108739
CY2016 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
67382
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2956218
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2873
CY2016 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
3456
CY2016 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-3773
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1120951
CY2016 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
49100
CY2016 us-gaap Revenues
Revenues
1103277
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
94094
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
3352 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0259
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2975164
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0058 pure
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M5D
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.72
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.9987
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8100 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.5125
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
101661 shares
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124459 shares
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
94094
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2873
CY2016 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
658293
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1060892 shares
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1361000
CY2016 myo Differed Offering Costs
DifferedOfferingCosts
438237
CY2016 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePriceExercisable
0
CY2016 myo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePriceExercisable
0
CY2016 myo Preferred Stock Accretion Of Redemption Discount Premium
PreferredStockAccretionOfRedemptionDiscountPremium
108739

Files In Submission

Name View Source Status
0001193125-18-079222-index-headers.html Edgar Link pending
0001193125-18-079222-index.html Edgar Link pending
0001193125-18-079222.txt Edgar Link pending
0001193125-18-079222-xbrl.zip Edgar Link pending
d465047d10k.htm Edgar Link pending
d465047dex1034.htm Edgar Link pending
d465047dex231.htm Edgar Link pending
d465047dex311.htm Edgar Link pending
d465047dex312.htm Edgar Link pending
d465047dex321.htm Edgar Link pending
d465047dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g465047g31n17.jpg Edgar Link pending
myo-20171231.xml Edgar Link completed
myo-20171231.xsd Edgar Link pending
myo-20171231_cal.xml Edgar Link unprocessable
myo-20171231_def.xml Edgar Link unprocessable
myo-20171231_lab.xml Edgar Link unprocessable
myo-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending